BIOMARIN PHARMACEUTICAL INC Accrued Income Taxes, Current
BIOMARIN PHARMACEUTICAL INC (BMRN) had Accrued Income Taxes, Current of $9.14 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedIncomeTaxesCurrent · last filed 2026-08-06
- 2026-06-30: Accrued Income Taxes, Current $9.14M.
- 2026-03-31: Accrued Income Taxes, Current $3.01M.
- 2025-12-31: Accrued Income Taxes, Current $3.67M.
- 2025-09-30: Accrued Income Taxes, Current $22.61M.
| Period end | Accrued Income Taxes, Current |
|---|---|
| 2026-06-30 | $9.14M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $3.01M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $3.67M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $22.61M 10-Q · filed 2025-10-28 |
| 2025-06-30 | $13.40M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $23.94M 10-Q · filed 2025-05-02 |
| 2024-12-31 | $12.57M 10-K · filed 2026-02-26 |
| 2024-09-30 | $21.04M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $18.86M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $6.07M 10-Q · filed 2024-04-26 |
| 2023-12-31 | $2.65M 10-K · filed 2025-02-24 |
| 2023-09-30 | $11.27M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $18.29M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $22.39M 10-Q · filed 2023-04-28 |
| 2022-12-31 | $16.21M 10-K · filed 2024-02-26 |
| 2021-12-31 | $1.21M 10-K · filed 2023-02-27 |
| 2018-09-30 | $0.00 10-Q · filed 2018-10-26 |
| 2017-12-31 | $5.53M 10-Q · filed 2018-10-26 |
| 2012-06-30 | $0.00 10-Q · filed 2012-08-02 |
| 2012-03-31 | $399.00K 10-Q · filed 2012-04-30 |
| 2011-12-31 | $713.00K 10-Q · filed 2012-08-02 |
| 2011-09-30 | $159.00K 10-Q · filed 2011-10-31 |
| 2011-06-30 | $112.00K 10-Q · filed 2011-08-01 |
| 2010-12-31 | $529.00K 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |